CureVac upgraded by UBS with a new price target
$CVAC
Biotechnology: Pharmaceutical Preparations
Health Care
UBS upgraded CureVac from Neutral to Buy and set a new price target of $18.00 from $8.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/13/2025 | $5.00 | Buy → Hold | Jefferies |
| 4/25/2024 | $12.00 → $4.00 | Outperform → Market Perform | Leerink Partners |
| 6/8/2023 | $13.00 | Outperform | SVB Securities |
| 1/19/2023 | $8.00 → $18.00 | Neutral → Buy | UBS |
| 1/9/2023 | $9.00 → $21.00 | Hold → Buy | Jefferies |
| 1/21/2022 | $55.00 → $20.00 | Neutral → Underperform | B of A Securities |
| 1/18/2022 | $52.00 | Market Outperform | JMP Securities |
| 10/22/2021 | $35.00 | Hold | Deutsche Bank |
425 - CureVac N.V. (0001809122) (Subject)
6-K - CureVac N.V. (0001809122) (Filer)
SCHEDULE 13D/A - CureVac N.V. (0001809122) (Subject)